State Street’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-2,845,839
| Closed | -$113M | – | 4432 |
|
|
2024
Q1 | $113M | Buy |
2,845,839
+1,455,810
| +105% | +$43M | 0.01% | 1227 |
|
|
2023
Q4 | $26.5M | Buy |
1,390,029
+784,484
| +130% | +$10.9M | ﹤0.01% | 2053 |
|
|
2023
Q3 | $6.93M | Buy |
605,545
+32,703
| +6% | +$402K | ﹤0.01% | 2765 |
|
|
2023
Q2 | $5.89M | Buy |
572,842
+226,171
| +65% | +$2.04M | ﹤0.01% | 2919 |
|
|
2023
Q1 | $2.68M | Buy |
346,671
+43,253
| +14% | +$345K | ﹤0.01% | 3236 |
|
|
2022
Q4 | $2.23M | Buy |
303,418
+24,436
| +9% | +$156K | ﹤0.01% | 3346 |
|
|
2022
Q3 | $2.01M | Buy |
278,982
+10,900
| +4% | +$89.8K | ﹤0.01% | 3416 |
|
|
2022
Q2 | $2.28M | Buy |
268,082
+47,461
| +22% | +$409K | ﹤0.01% | 3432 |
|
|
2022
Q1 | $1.98M | Buy |
220,621
+14,609
| +7% | +$126K | ﹤0.01% | 3567 |
|
|
2021
Q4 | $2.85M | Buy |
206,012
+8,216
| +4% | +$102K | ﹤0.01% | 3513 |
|
|
2021
Q3 | $2.11M | Buy |
197,796
+24,677
| +14% | +$227K | ﹤0.01% | 3597 |
|
|
2021
Q2 | $1.56M | Buy |
+173,119
| New | +$1.88M | ﹤0.01% | 3588 |
|
|
2018
Q4 | – | Sell |
-10,126
| Closed | -$64K | – | 3793 |
|
|
2018
Q3 | $64K | Buy |
+10,126
| New | +$70.8K | ﹤0.01% | 3684 |
|
|
2016
Q2 | – | Sell |
-11,124
| Closed | -$186K | – | 3775 |
|
|
2016
Q1 | $186K | Buy |
11,124
+475
| +4% | +$9.51K | ﹤0.01% | 3499 |
|
|
2015
Q4 | $330K | Buy |
+10,649
| New | +$364K | ﹤0.01% | 3417 |
|
State Street's ALPN Position: Q2 2024 in Review
State Street sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,845,839 shares — an estimated $113M sold.
State Street first reported a position in ALPN in Q4 2015 and held it in 15 quarters. The position peaked at $113M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- State Street reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- State Street sold 2,845,839 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $113M.
- State Street first reported a position in Alpine Immune Sciences Inc in Q4 2015 and held it in 15 quarters.
- State Street's Alpine Immune Sciences Inc position peaked at $113M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.